Lv3
298 积分 2024-09-29 加入
Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries
14小时前
待确认
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
14小时前
已完结
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
14小时前
已完结
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
15小时前
已完结
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
15小时前
已完结
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
15小时前
已完结
CLO25-072: A Multicenter, Randomized, Controlled, Non-Inferiority Study of Narlumosbart Compared With Denosumab in the Treatment of Bone Disease in Patients With Multiple Myeloma
29天前
已关闭
Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta‐Analysis
1个月前
已完结
CLO25-072: A Multicenter, Randomized, Controlled, Non-Inferiority Study of Narlumosbart Compared With Denosumab in the Treatment of Bone Disease in Patients With Multiple Myeloma
1个月前
已关闭
Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point?
1个月前
已完结
皖公网安备34019202002308
